Silexion Therapeutics Corp. (SLXN) Validates Native Lipid Uptake Mechanism for SIL204

Silexion Therapeutics reported translational data showing SIL204 uses circulating lipoproteins for cellular entry and KRAS knockdown in vitro, supporting systemic administration in its Phase 2/3 program.Material DetailsContext by AI AnalystThis is mid-stage mechanistic validation supporting Silexio…